July 2024

SHANGHAI, July 8, 2024 /PRNewswire/ — BioCity Biopharma (BioCity) announced its endothelin receptor type A (ETA) selective antagonist SC0062 met the primary endpoint of proteinuria reduction in the 2-SUCCEED trial: a randomized, double-blind, placebo-controlled, dose-ranging phase 2 clinical t

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: